Åkerö

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO

Retrieved on: 
Monday, April 8, 2024
Patient, EFX, LLP, News, Åkerö, Fibrosis, Pomerantz, NASH

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO).
  • The investigation concerns whether Akero and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • In addition, Akero added that 12 patients, including 11 in EFX groups, discontinued the trial due to drug-related adverse events.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Akero Therapeutics Shareholders

Retrieved on: 
Thursday, March 28, 2024
SAN, LLP, Åkerö

The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

Key Points: 
  • The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
  • What if I purchased Akero securities?
  • If you purchased securities and suffered significant losses on your investment, join our investigation now:
    There is no cost or obligation to you.
  • Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program.

AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)

Retrieved on: 
Wednesday, March 20, 2024
Notice, Patient, Fibrosis, News, LLP, Åkerö, Learning, Investor's Business Daily

The result wasn’t statistically significant.” On this news, Akero stock fell sharply.

Key Points: 
  • The result wasn’t statistically significant.” On this news, Akero stock fell sharply.
  • Abraham, Fruchter & Twersky, LLP (www.aftlaw.com) is a law firm based in New York and maintaining an office in California.
  • Abraham, Fruchter & Twersky, LLP has extensive experience in litigating on behalf of investors.
  • If you have any questions about this Notice, the investigation, your rights or your interests, please contact:

Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Shareholders

Retrieved on: 
Friday, March 15, 2024
SAN, LLP, Åkerö

The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

Key Points: 
  • The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
  • What if I purchased Akero securities?
  • If you purchased securities and suffered losses on your investment, join our investigation now:
    Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.
  • Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program.

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Retrieved on: 
Friday, March 8, 2024
Varick Street, Attention, SAN, Jefferies Group, Prospectus, Telephone, 2nd Floor, Åkerö, Sale, Exercise, Equity capital markets, DSM-IV codes, Broadridge Financial Solutions, Therapy, Morgan Stanley, Madison Avenue, Patient, Evercore, Jefferies, Security (finance)

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $366.9 million.

Key Points: 
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $366.9 million.
  • J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI acted as joint book-running managers for the offering.
  • The shares of common stock were offered by Akero pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC).
  • A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on March 6, 2024.

Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Akero Therapeutics Shareholders

Retrieved on: 
Monday, February 26, 2024
LLP, SAN, Åkerö

The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

Key Points: 
  • The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
  • What if I purchased Akero securities?
  • If you purchased securities and suffered significant losses on your investment, join our investigation now:
    There is no cost or obligation to you.
  • Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program.

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
NAFLD, Safety, SAN, Therapy, Cirrhosis, Clinical trial, Patient, DSM-IV codes, Diabetes, Lipid, Lipoprotein, Research, Liver injury, FDA, Extrapyramidal system, EFX, CMO, Biomarker, Fibrosis, AND, Histology, NASH, F4, Biopsy, Pharmaceutical industry, Medical imaging, Cryptocurrency, Åkerö

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.
  • Key secondary endpoints will include changes in biomarkers of liver fibrosis as well as measures of glycemic control and lipids.
  • Akero's cash, cash equivalents and short-term and long-term marketable securities for the period ended September 30, 2023 were $613.0 million.
  • Total operating expenses were $46.6 million for the three-month period ended September 30, 2023, compared to $36.1 million for the comparable period in 2022.

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023
Safety, Randomness, DSM-IV codes, Efficacy, Therapy, Cohort, AASLD, Cirrhosis, T2D, Patient, EFX, Liver, Risk compensation, Non-alcoholic fatty liver disease, Poster, NASH, Type 2 diabetes, Fibrosis, Pharmaceutical industry, Vaccine, Boston, Åkerö

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced it will present a late-breaking oral presentation and a poster featuring its lead product candidate efruxifermin (EFX) at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023 being held November 10-14 in Boston, MA.

Key Points: 
  • Another analysis of the 36-week SYMMETRY study data showed that the trend for EFX to reverse cirrhosis did not appear to be attributable to concomitant use of GLP-1.
  • The poster describes data from SYMMETRY Cohort D, which evaluated treatment of EFX in combination with a GLP-1 receptor agonist in patients with F1-F3 NASH/MASH and Type 2 diabetes.
  • The poster also includes subgroup analyses from HARMONY showing that improvements in liver histology among F2-F3 NASH/MASH patients associated with EFX treatment with EFX, do not appear to be attributable to concomitant use of GLP-1.
  • We therefore believe that longer periods of treatment with EFX may result in higher rates of fibrosis improvement, including cirrhosis reversal.

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip

Retrieved on: 
Tuesday, October 10, 2023
Lipoprotein, Liver injury, Health, Cirrhosis, Decompensation, Liver, Week, DSM-IV codes, Safety, NASH, Therapy, Fatty liver disease, F1, Collagen, Patient, Fibrosis, Terminal, EFX, Copper, Pharmaceutical industry, Medical imaging, Åkerö

SOUTH SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH).

Key Points: 
  • In addition, 4% of patients in each of the EFX-treated groups experienced a three- or two-stage fibrosis improvement without worsening of NASH – from compensated cirrhosis (F4) to F1 or F2, compared with 0% for placebo.
  • Statistically significant improvements were also observed for both EFX groups in non-invasive markers of liver injury and fibrosis, insulin sensitization and lipoproteins.
  • I’m encouraged that statistically significant improvements on multiple measures of NASH pathogenesis were observed in EFX-treated patients.
  • This underlines the high unmet medical need to at least arrest progression or preferably reverse cirrhosis due to NASH.

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Retrieved on: 
Monday, October 9, 2023
Histology, Diabetes, DSM-IV codes, Safety, Fatty liver disease, NASH, Therapy, Event, Webcast, Cirrhosis, SAN, Fibrosis, EFX, Patient, Pharmaceutical industry, Online shopping, Åkerö

ET to share topline week 36 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH).

Key Points: 
  • ET to share topline week 36 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH).
  • The topline results will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins as well as safety and tolerability.
  • The company will host a conference call and webcast with slide presentation at 8:00 a.m.
  • The live webcast will be available on the Events & Presentations page of the Akero website, with the recording and presentation available immediately following the event.